Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation

Rhea-AI Summary

Ampio Pharmaceuticals, Inc. announced the receipt of an unqualified audit opinion with a going concern explanation in its Annual Report for 2023. The audit opinion does not alter the financial statements or the Form 10-K. This announcement complies with NYSE American requirements.

Positive

• None.

Negative

• The explanatory paragraph regarding the going concern in the audit opinion might raise concerns about Ampio's financial stability and ability to continue operations.
• The need for a going concern paragraph in the audit opinion could indicate potential financial challenges for Ampio Pharmaceuticals.

Insights

Financial Analyst

The inclusion of a 'going concern' paragraph in Ampio Pharmaceuticals' audited financial statements signals a noteworthy caution for investors and stakeholders. This term typically indicates that there are substantial doubts about the company's ability to continue operations for the foreseeable future, usually the next twelve months. It is a red flag in financial reporting that can affect investor confidence and has implications for the company's stock price and creditworthiness.

From a financial analysis perspective, the 'going concern' note may lead to a reevaluation of the company's long-term viability, impacting its ability to raise capital and possibly triggering covenants in existing debt agreements. Stakeholders should be attentive to the company's forthcoming strategies to address these concerns, such as securing new funding, restructuring operations, or exploring strategic partnerships.

It is also important to consider the industry context. Pharmaceutical companies often face high R&D costs with uncertain returns, which can lead to financial strain. Investors should compare the company's financial health with industry peers to get a clearer picture of its position.

Market Research Analyst

Receiving a 'going concern' opinion can impact not only Ampio Pharmaceuticals but also the broader market's perception of the pharmaceutical sector, especially for small-cap companies on the NYSE American exchange. This type of news can lead to increased market volatility for similar stocks, as investors may become more cautious and risk-averse, seeking safer investment havens.

Analysing market trends, it's evident that companies with similar warnings often face decreased liquidity and heightened scrutiny from analysts and regulators. Market sentiment can shift, potentially affecting not only Ampio's stock but also peer companies as investors reassess the risk profiles of their portfolios. It's important for market participants to monitor Ampio's subsequent actions, such as strategic pivots or fundraising efforts, which could serve as indicators for the company's future market performance.

Legal Expert

The disclosure made by Ampio Pharmaceuticals adheres to NYSE American LLC Company Guide Section 610(b) requirements, which stipulate the necessity for public companies to announce the receipt of an audit opinion with a 'going concern' notice. This transparency is critical for maintaining legal compliance and ensuring that shareholders and the investing public are fully informed of material financial conditions that may affect their investment decisions.

Legally, the company's proactive communication helps mitigate the risk of potential shareholder litigation, as it demonstrates that Ampio is taking the necessary steps to disclose its financial challenges. Investors and analysts should be aware of the company's legal obligations and the steps they are taking to maintain compliance, as these actions can influence the company's reputation and investor relations.

ENGLEWOOD, Colo., April 3, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 27, 2024 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. Further discussion is included in footnote 2 of the Company's financial statements included in the Company's Annual Report on Form 10-K. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph. This announcement does not represent any change or amendment to the Company's financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2023.

For more information, contact:
Ampio Pharmaceuticals, Inc.
Michael A. Martino
Chief Executive Officer
mmartino@ampiopharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-received-audit-opinion-with-going-concern-explanation-302107593.html

SOURCE Ampio Pharmaceuticals, Inc.

FAQ

What did Ampio Pharmaceuticals announce regarding its audit opinion?

Ampio Pharmaceuticals announced the receipt of an unqualified audit opinion with a going concern explanation in its Annual Report for 2023.

When was the Annual Report for 2023 filed by Ampio Pharmaceuticals?

The Annual Report for 2023 was filed on March 27, 2024.

What does the presence of a going concern paragraph in the audit opinion signify?

The going concern paragraph in the audit opinion indicates doubts about Ampio Pharmaceuticals' ability to continue operations.

Why is the announcement regarding the audit opinion necessary?

The announcement is required by NYSE American Company Guide Section 610(b) for audit opinions containing a going concern paragraph.

Who is the Chief Executive Officer of Ampio Pharmaceuticals?

The Chief Executive Officer of Ampio Pharmaceuticals is Michael A. Martino.